Ignite Creation Date:
2024-05-06 @ 8:04 PM
Last Modification Date:
2024-10-26 @ 3:19 PM
Study NCT ID:
NCT06231446
Status:
RECRUITING
Last Update Posted:
2024-01-30
First Post:
2024-01-18
Brief Title:
Extracorporeal Membrane Oxygenation for Respiratory Failure Patients
Sponsor:
China-Japan Friendship Hospital
Organization:
China-Japan Friendship Hospital
Study Overview
Official Title:
A Multicenter Prospective Cohort Study of the Clinical Characteristics and Prognosis of Respiratory Failure Patients With ECMO Therapy
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The present study is a multicentre cohort study Respiratory failure patients treated with extracorporeal membrane oxygenation ECMO were enrolled Clinical data before and during ECMO treatment were collected Clinical data before and during ECMO treatment were collected By this retrospective clinical data and prospective study to observe the current status of respiratory failure patients treated with ECMO in China analyze the clinical characteristics and prognosis of patients and explore the clinical prevention and treatment strategies of major complications of ECMO
Detailed Description:
Extracorporeal membrane oxygenation ECMO is the ultimate life support for critically ill patients However ECMO was developed relatively late in China and the large number of applications in the field of respiratory failure originated from the 2009 H1N1 influenza epidemic in China Since then the number of respiratory failure patients with ECMO has increased year by year Nevertheless there are still many problems about ECMO therapy for respiratory failure in China mainly as follows1 Lack of real-world clinical data on ECMO Most centers do not have their own databases lack long-term follow-up and are unable to establish a mature ECMO quality management system 2 Lack of ECMO-related biological sample libraries 3 Risk factors for major complications such as thrombosis and hemorrhage ventilator-associated pneumonia and bloodstream infections are still unclear At present most of the experience in the prevention and treatment of major complications of ECMO comes from foreign studies and clinical studies have confirmed that the sensitivity and specificity of the currently commonly used biological indicators in the prediction and early warning of complications are not ideal Therefore there is an urgent need to carry out research on new biomarkers based on the establishment of clinical databases and biospecimen libraries We retrospectively collected clinical data on respiratory failure patients treated with ECMO from June 2019 from five hospitals and prospectively enrolled respiratory failure patients treated with ECMO from October 2022 from five hospitals By this cohort study to establish clinical databases and biospecimen libraries and analyze the clinical characteristics and prognosis of patients and explore the clinical prevention and treatment strategies of major complications of ECMO
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None